CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
about
CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing.Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymesPolymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.Functional gene variants of CYP3A4.CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomesRelationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.Response to "CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients".Severe sunitinib-induced myelosuppression in a patient with a CYP 3A4 polymorphism.Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype.
P2860
Q34360012-88AB348F-9431-4D26-BC55-A5641BFD77B6Q36359679-3A696CD1-D86B-431B-B392-A939C10584D5Q36776572-BCD9AF42-6E99-493E-B6FA-3F393A23675FQ37662607-23437BC7-DDC9-4EDD-9133-F43018731DB4Q37678060-21E6F6A1-41BC-4FCB-91E0-0A0CEDE808E6Q38220008-D53906CC-3CC0-4588-9EB9-8ABB15966D69Q39534657-264CD9F0-5332-4F88-A94B-30E170B623DFQ41328717-FA0CF348-5B2A-4C64-8136-931F115BC696Q42215557-EFC0280F-34E6-46DB-B054-3325F7698C89Q44337894-8B716EE3-E3E9-4E5D-9619-93E182CDFA5EQ45279289-1AAC32F3-88E9-4B2D-8A17-7C79BA59750BQ51000835-179D86AD-3850-4344-B011-BF20110CCEC3Q52759903-FCDC75AF-590B-4967-865A-2F6373CBF1AAQ53621686-B4FCB75D-BC98-4650-8FF8-108D8585EF04Q55506508-2390A972-9DF3-4C6A-A119-30CB9F1F9406
P2860
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
CYP3A4 intron 6 C>T SNP (CYP3A ...... es midazolam and erythromycin.
@en
CYP3A4 intron 6 C>T SNP (CYP3A ...... es midazolam and erythromycin.
@nl
type
label
CYP3A4 intron 6 C>T SNP (CYP3A ...... es midazolam and erythromycin.
@en
CYP3A4 intron 6 C>T SNP (CYP3A ...... es midazolam and erythromycin.
@nl
prefLabel
CYP3A4 intron 6 C>T SNP (CYP3A ...... es midazolam and erythromycin.
@en
CYP3A4 intron 6 C>T SNP (CYP3A ...... es midazolam and erythromycin.
@nl
P2093
P2860
P356
P1433
P1476
CYP3A4 intron 6 C>T SNP (CYP3A ...... es midazolam and erythromycin.
@en
P2093
Anne-Joy de Graan
Annemieke Nieuweboer
Kellie A Charles
Laure Elens
Ron H J Mathijssen
Ron H N van Schaik
Stephen J Clarke
Vincent Haufroid
P2860
P304
P356
10.2217/PGS.12.202
P577
2013-01-01T00:00:00Z